KRAS and familial pancreatic carcinoma: Targeting this axis—either by disrupting KRAS signaling or interfering with LD formation and lipid storage—could offer a promising strategy to enhance the efficacy of gemcitabine and other chemotherapeutic agents in KRAS-mutant pancreatic cancers [18,28].